Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Caladrius Biosciences Inc.
DescriptionCD34 cell therapy
Molecular Target CD34
Mechanism of Action 
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase I
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat critical limb ischemia (CLI)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today